NCT07690228尚未招募1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacology of GSM-779690T in Healthy Adult Participants
Acta Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2026年8月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Safety Evaluation
研究概览
简要总结
A Phase 1, single-centre, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple dose regimens of GSM-779690T in healthy adults. This first-in-human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GSM-779690T.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
Double (participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •to be eligible for enrollment:
- •Healthy and aged 18-55 years.
- •Current Mini Mental State Examination (MMSE) score between 27 and 30 at screening.
- •Able to provide their own written informed consent.
- •Good general health with no disease expected to interfere with the study.
- •Able to read, speak, and understand English to ensure compliance with cognitive testing and study visit procedures.
- •Must be ambulatory and be willing to remain domiciled in the clinic for the required study procedures.
- •Contraception requirements:
- •a. Women of childbearing potential (WOCBP) must agree to use a highly effective method of birth control (confirmed by the Investigator) from enrollment, throughout the study duration, and have a negative pregnancy test result at screening. Highly effective methods of birth control (those with a failure rate of < 1% per year when used consistently and correctly) include: (i) Combined (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal, (ii) Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable, (iii) Intrauterine device, (iv) Intrauterine hormone-releasing system, (v) Bilateral tubal occlusion, (vi) Tubal ligation, (vii) Sexual abstinence, i.e., refraining from heterosexual intercourse, or (viii) Vasectomized sexual partner (provided that partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has received medical assessment of the surgical success).
- •b. Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or who are postmenopausal.
- •c. Males with childbearing partners must be willing to practice sexual abstinence or use double-barrier protection during study treatment and until 1 week after the last dose of study treatment.
- •Participants who meet any of the following criteria must not be included in the study:
- •A history of any current or clinically significant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, ophthalmologic, hematological, or allergic disease or metabolic disorder.
- •Use of any concomitant medications is prohibited, other than prescribed birth control methods stable 30 days prior to Day -
- •A history of chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or procedures that require intravenous contrast within 72 hours of study initiation.
- •A history of a psychiatric disorder such as schizophrenia, bipolar disorder or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM).
- •Any evidence of current suicidal ideation or any previous suicide attempt as evaluated by the Columbia-Suicide Severity Rating Scale (C-SSRS).
- •Diagnosis of a neurodegenerative disease or dementia, including but not limited to Alzheimer's disease (AD), Parkinson's disease, and Huntington's disease.
排除标准
- 未提供
研究组 & 干预措施
Active Drug GSM-779690T
Active Comparator
干预措施: GSM-779690T (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Safety Evaluation
时间窗: From enrollment up to 7 days post dosing in the SAD and up to 21 days post dosing in the MAD.
The number of participants with Adverse Events, with abnormal Vital Signs, abnormal Physical Examination findings, abnormal laboratory Test results, abnormal 12-lead Electrocardiogram (ECG) readings.
次要结局
- Area under the plasma concentration curve versus time curve (AUC) after single GSM-779690T dose.(At pre-dose, post dose on day 1, Day 2, Day 3, and Day 4.)
- Area under the plasma concentration versus time curve (AUC) after multiple GSM-779690T doses.(At Pre-Dose, Day 3, Day 5, Day 7, Day 9, Day 11, Day 13, Day 14, Day 15, Day 16 Post-Dose.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight AdultsNCT07307274Syntis Bio55
招募中
1 期
A First-in-Human Single and Multiple Ascending Dose Study of MT-251NCT07423299Mirador Therapeutics, Inc.70
招募中
1 期
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese ParticipantsNCT07626515Hoffmann-La Roche36
招募中
2 期
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LNNCT07363460Haisco Pharmaceutical Group Co., Ltd.105
招募中
1 期
A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis ParticipantsAtopic DermatitisNCT07488065Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.90